High Dose Risankizumab for Psoriasis

Part of paid clinical trials in Portland, Oregon.

Sponsor
Oregon Medical Research Center
Study ID
NCT05283135
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • risankizumab — DRUG
    Risankizumab (Skyrizi) is an anti-IL-23 antibody being investigated for the treatment of multiple inflammatory diseases, including psoriasis, Crohn's disease, ulcerative colitis, and psoriatic arthritis.

Study Details

This pilot study explores higher than standard doses of risankizumab for plaque psoriasis, to see effects on resident memory T cells and skin clearance.

Key Dates

Start date
Mar 1, 2022
Status verified
Oct 2025
Primary completion
Aug 7, 2023
Completion
Jul 10, 2024

Study Design

Enrollment
20 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: risankizumab subcutaneous injection 600 mg (4x dosing) at Weeks 0, 4, and 16
  • Experimental: risankizumab subcutaneous injection 300 mg (2x dosing) at Weeks 0, 4, and 16

Primary Outcome Measure

CD8+ Trm1 Cells in Lesional Skin at Baseline and Week 52 [ Time Frame: 52 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Oregon Medical Research CenterPortlandOregon97201-

Related coverage on Hipa.ai

Find similar trials in Portland, OR

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Oregon Medical Research Center· Portland, OR

Related Studies